**Swiss Neuro-Oncology Symposium, 17.5.2019**

Rot = zugesagt

**9:30 Welcome** (S. Hofer, U. Roelcke)

**9:35-10:55 Update on diagnostics** (U. Roelcke, A. von Hessling, M. Hegi)

9:35-9:55 MRI perfusion and diffusion parameters ( R. Wiest)

9:55-10:15 fMRI, tractography (Chr. Stippich)

10:15-10:35 PET and Radiomics (U. Roelcke)

10:35-10:55 new glioma entities beyond the WHO classification (E. Rushing)

 glioma pathways to be considered for novel therapies (M. Hegi)

**10:55-11:10 Coffee break**

**11:10-12:45 Old & novel therapies** (S.Hofer, Chr. Riklin)

11:10-11.55 Prevention of methotrexate toxicity (C. Largadier, St. Aebi)

12.55-12:25 CCNU upfront for MGMT methyl GBM & options for recurrent GBM? (A.Hottinger)

12:25-12:45 Immunotherapy in glioma: success or failure? (M. Weller)

12.45- 13.15 Combinatorial microglia & tumor targeting against glioblastoma (G. Hutter)

**13:15-14:00 Lunch break**

**14:00-14:55 Controversies in Neurooncology** (Plasswilm, Studer, Kothbauer)

13:35-13:55 Extent of resection versus functional preservation (Ph. Schucht)

 Neuropsychology: late toxicity of current glioma treatment (T. Pflugshaupt)

13:55-14:15 Low-grade glioma post surgery: wait or treat, De-escalation: when and how? (Th. Hundsberger)

14:35-14:55 How to minimize radiation-induced brain toxicity (G. Studer)

**14:55-15:10 Coffee break**

**15:10-16:50 Rare topics** (A.Hottinger, M. Reinert)

15:10-15:30 IDHwt glioma with potential actionable targets: FGFR, Histon, BRAF (P.Roth)

15:30-15:50 Medulloblastoma in adults (P. Hau)

15:50-16:10 Leptomeningeal disease: manifestation and treatment (T. Pukrop)

16:10-16:30 Neurological side effects of Checkpoint Inhibitors (E. Wilder Smith)

**16:50-17:00 Closing remarks** K. Kothbauer, G. Studer